头孢哌酮钠他唑巴坦钠降阶梯疗法治疗老年慢性阻塞性肺疾病对气道重塑及炎症因子的影响
The Influence of Cefoperazone Sodium and Tazobactam Sodium Step-Down Therapy on Airway Remodeling and Inflammatory Factors in the Treatment of Elderly Patients with Chronic Obstructive Pulmonary Disease
摘要: 目的:观察头孢哌酮钠他唑巴坦钠降阶梯疗法治疗老年慢性阻塞性肺疾病对气道炎症与基质降解相关生物标志物及炎症因子的影响。方法:选取我院老年慢性阻塞性肺疾病患者90例(2022年1月至2025年12月),采用随机数字表法分为常规治疗的对照组(45例)与头孢哌酮钠他唑巴坦钠降阶梯疗法治疗的观察组(45例)。观察患者肺功能指标、气道炎症与基质降解相关生物标志物、炎症因子水平。结果:与对照组相比,观察组肺功能指标改善好,气道炎症与基质降解相关生物标志物改善好,炎症因子水平低,P < 0.05;两组痰培养阳性率及细菌谱分布对比,P > 0.05。结论:老年慢性阻塞性肺疾病治疗中采用头孢哌酮钠他唑巴坦钠降阶梯疗法有利于肺功能、气道炎症与基质降解相关生物标志物改善,降低炎症因子水平,值得借鉴。
Abstract: Objective: To observe the effects of cefoperazone sodium and tazobactam sodium step-down therapy on airway inflammation and matrix degradation-related biomarkers and inflammatory factors in the treatment of elderly patients with chronic obstructive pulmonary disease. Methods: A total of 90 elderly patients with chronic obstructive pulmonary disease in our hospital (from January 2022 to December 2025) were selected and randomly divided into a control group (45 cases) treated with conventional therapy and an observation group (45 cases) treated with cefoperazone sodium and tazobactam sodium stepwise therapy by random number table method. The pulmonary function indicators of the patients, biomarkers related to airway inflammation and matrix degradation, and the levels of inflammatory factors were observed. Results: Compared with the control group, the pulmonary function indicators in the observation group improved better, the biomarkers related to airway inflammation and matrix degradation improved better, and the levels of inflammatory factors were low, P < 0.05. The comparison of the positive rate of sputum culture and the distribution of bacterial spectra between the two groups showed P > 0.05. Conclusion: The stepwise therapy of cefoperazone sodium and tazobactam sodium in the treatment of elderly chronic obstructive pulmonary disease is beneficial for improving biomarkers related to lung function, airway inflammation and matrix degradation, and reducing the levels of inflammatory factors. It is worth learning from.
文章引用:倪广帅, 李钊. 头孢哌酮钠他唑巴坦钠降阶梯疗法治疗老年慢性阻塞性肺疾病对气道重塑及炎症因子的影响[J]. 医学诊断, 2026, 16(1): 146-151. https://doi.org/10.12677/md.2026.161020

参考文献

[1] 王刚, 刘建新, 张峰, 等. 头孢哌酮钠舒巴坦钠治疗老年慢性阻塞性肺疾病合并肺部感染患者的疗效及对凝血功能的影响[J]. 中国药物应用与监测, 2025, 22(2): 211-214.
[2] 冯若梅, 李超. 哌拉西林他唑巴坦钠与头孢哌酮舒巴坦钠对老年慢阻肺合并感染患者的临床疗效评价[J]. 贵州医药, 2022, 46(9): 1420-1421.
[3] 张文龙, 赵伟峰, 王志刚. 胸腺肽联合头孢哌酮钠舒巴坦钠治疗慢性阻塞性肺疾病合并肺部感染患者的效果[J]. 中国民康医学, 2024, 36(18): 34-36.
[4] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2007年修订版) [J]. 中华内科杂志, 2007, 46(3): 254-261.
[5] 张宁霞, 高亮, 康贝贝. 布地格福吸入气雾剂联合头孢哌酮钠舒巴坦钠治疗慢性阻塞性肺疾病患者的效果[J]. 四川生理科学杂志, 2025, 47(1): 50-53.
[6] 黄万强. 泼尼龙琥珀酸钠联合头孢哌酮钠舒巴坦钠与哌拉西林他唑巴坦对慢性阻塞性肺疾病急性加重期患者的疗效对比研究[J]. 基层医学论坛, 2024, 28(23): 31-34.
[7] 郭力源, 李朝红, 姬春阳. 头孢哌酮钠舒巴坦钠联合喹诺酮治疗慢性阻塞性肺疾病急性加重期的效果研究[J]. 中国实用医刊, 2025, 52(4): 111-113.
[8] 刘义珍, 郭铭花, 张焕新. 头孢哌酮钠舒巴坦钠与莫西沙星对急性加重期慢性阻塞性肺疾病患者疗效及不良反应的影响分析[J]. 系统医学, 2024, 9(24): 74-77.
[9] 王小燕, 朱媛君, 倪高顺. 甲泼尼龙琥珀酸钠联合吸入性乙酰半胱氨酸治疗慢性阻塞性肺疾病合并重症肺部感染的临床疗效[J]. 医学临床研究, 2023, 40(12): 1953-1955.